Zanubrutinib for treating Waldenstrom’s macroglobulinaemia

2.1 Zanubrutinib (Brukinsa, BeiGene) has a marketing authorisation in the UK for 'the treatment of adult patients with Waldenström's macroglobulinaemia (WM) in adults who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics for zanubrutinib.

2.3 The list price of zanubrutinib 120x80 mg capsules is £4,928.65 (excluding VAT; company submission). The company has a commercial arrangement. This makes zanubrutinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.